OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.…
OncoZenge: 92% tecknat – får in 25 miljoner netto
OncoZenge (STO: ONCOZ) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 2.855 SEK on 20 November 2026, down 49.8% over 52 weeks. Its 52-week range is 2.805 SEK to 10.28 SEK: the price is 72.2% below the high and 1.8% above the low.
Its market capitalisation is 71.51M SEK.
OncoZenge reports return on equity of -188.0%.
It holds more cash than debt, a net cash position of 24.30M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 8.000 SEK is 180.2% above the current price.
No upcoming events tracked.